USP’s Sheehan and Liu talk at AAPS PharmSci 360 abou getting novel excipients past the monograph hurdle through early engagement with FDA.
|Videos|May 30, 2023
CAR-T Cell Therapies Entering the Mainstream of Cancer Clinical Trials & Treatment
Author(s)Medidata
KEY LEARNING OBJECTIVES
- Audience will have an understanding how Medidata can have an impact with Clinical Trial pharma and bio tech firms that are working in this therapeutic area
- What are the challenges that CAR-T developers face and how can data help address those challenges
- How is Medidata AI “data” different from other data providers
Related to this article
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
The business case for regulated AI turns on the cost of producing an outcome that the quality system can accept.
In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
Structural modifications can improve peptide stability, solubility, and absorption to enable effective oral delivery.
The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
Improving Oral Peptide Delivery Through Structural Modifications
4
Potent APIs Amplify Carryover Risk: AAPS PharmSci 360 2026
5